PITCH is Collision’s startup competition that brings together the world’s leading early stage startups to compete on stage.
PITCH is open to any ALPHA and BETA startup exhibiting at Collision that has received less than $5 million in funding to date and has not undergone any notable changes to its business model in the past three years.
After two rounds of pitching, a British Columbia startup was selected as one of three 2024 PITCH finalists.
Victoria’s VoxCell BioInnovation, presented by Asees Kaur, will make their final presentation along with Toronto’s Biofect Innovations and Proceve on Thursday as Collision wraps up its Toronto activities.
VoxCell is a leading company in the field of tissue engineering, and yesterday at Collision they announced the launch of their first product, the Universal Bioink Kit.
VoxCell was named one of Techcouver’s 10 national startups to watch in 2023.
The Universal Bioink Kit is designed to revolutionize the field of 3D bioprinting by providing versatile and reliable bioinks that mimic the extracellular matrix of living tissues.
The kit stands out for its unique ability to replicate the chemical and mechanical properties of soft tissues, offering unparalleled compatibility with a range of bioprinting techniques, including extrusion-based and digital light processing (DLP) systems.
This ready-to-use bioink supports multiple media compatibility, allowing researchers to work with a variety of cell lines and open up new possibilities in tissue engineering.
